Endocrine resistance in breast cancer
-
Upload
seayat1103 -
Category
Health & Medicine
-
view
965 -
download
0
description
Transcript of Endocrine resistance in breast cancer
![Page 1: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/1.jpg)
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast
Cancer
N Engl J Med 2011 Dec 7.
Presenstor : CR周益聖 Instructor : VS趙大中
![Page 2: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/2.jpg)
Outline
• Adjuvant endocrine therapy in postmenopausal ER+ women
• Endocrine resistance after Adjuvant endocrine therapy
• Treating Endocrine resistance
![Page 3: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/3.jpg)
Part IAdjuvant endocrine therapy in postmenopausal ER+ women
![Page 4: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/4.jpg)
Tamoxifen & Recurrence
Lancet 365, 1687–1717 (2005).
41% reductions of risks of recurrence
![Page 5: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/5.jpg)
Lancet 365, 1687–1717 (2005).
Tamoxifen & Recurrence
![Page 6: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/6.jpg)
Tamoxifen & Mortality
Lancet 365, 1687–1717 (2005).
34% reductions of risks of mortality
![Page 7: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/7.jpg)
Tamoxifen & Mortality
Lancet 365, 1687–1717 (2005).
![Page 8: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/8.jpg)
Aromatase inhibitor (AI)
• Non-steroidal– block the peripheral conversion of androgens to
estrogens by inhibiting the heme porphyrin portion of aromatase
– Letrozole (Femara®) & Anastrozle (Arimidex®)• Steroidal– binding irreversibly to the androgen binding site– Exemestane (Aromasin®)
![Page 9: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/9.jpg)
Postmenopausal adjuvant endocrine therapy
Expert Rev. Anticancer Ther. 11(2), 277–286 (2011)
![Page 10: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/10.jpg)
Postmenopausal adjuvant endocrine therapy
Expert Rev. Anticancer Ther. 11(2), 277–286 (2011)
勝 (DFS)
Lancet 359, 2131–2139 (2002)
![Page 11: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/11.jpg)
Postmenopausal adjuvant endocrine therapy
Expert Rev. Anticancer Ther. 11(2), 277–286 (2011)
MA.17MA.17 Tamoxifen for 5 yearsLetrozole for 5 years
Placebo for 5 years
N. Engl. J. Med. 349, 1793–1802 (2003)
勝(DFS,OS in LN+
![Page 12: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/12.jpg)
Postmenopausal adjuvant endocrine therapy
Expert Rev. Anticancer Ther. 11(2), 277–286 (2011)
勝 (DFS and
OS)
Lancet 365, 1687–1717 (2005)
勝 (DFS and
DMFS)
J. Clin. Oncol. 23, 5138–5147 (2005)
![Page 13: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/13.jpg)
Postmenopausal adjuvant endocrine therapy
Expert Rev. Anticancer Ther. 11(2), 277–286 (2011)Lancet 366, 455–462 (2005)
勝(EFS)
![Page 14: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/14.jpg)
Postmenopausal adjuvant endocrine therapy
Expert Rev. Anticancer Ther. 11(2), 277–286 (2011)
勝 DFS and TTDR
N. Engl. J. Med. 353, 2747–2757 (2005)
J. Clin. Oncol. 25, 486–492 (2007)
N. Engl. J. Med. 361, 766–776 (2009)
25.8 months
![Page 15: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/15.jpg)
Postmenopausal adjuvant endocrine therapy
Expert Rev. Anticancer Ther. 11(2), 277–286 (2011)N. Engl. J. Med. 353, 2747–2757 (2005)
J. Clin. Oncol. 25, 486–492 (2007)
N. Engl. J. Med. 361, 766–776 (2009)
71 months
勝 OS trend
![Page 16: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/16.jpg)
Part IIEndocrine resistance after adjuvant endocrine therapy
![Page 17: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/17.jpg)
Loss of ER
1.Clonal selection2.Transcription suppression of ER geneby promotor methylation
Clin Cancer Res; 16(7); 1979–87.
![Page 18: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/18.jpg)
EGFR/HER2 overexpression
MAPK ↑
Clin Cancer Res; 16(7); 1979–87.
![Page 19: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/19.jpg)
Clin Cancer Res; 16(7); 1979–87.
![Page 20: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/20.jpg)
Nat Rev Cancer 2004 May;4(5):335-48
![Page 21: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/21.jpg)
Clin Cancer Res 2005;11(14) July 15, 2005
S6K1 ↓P-S6 ↓
RAD001
4E-BP1 ↑
eIF-4E ↑
eIF-4G ↓
![Page 22: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/22.jpg)
Clin Cancer Res 2005;11(14) July 15, 2005
![Page 23: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/23.jpg)
J Clin Oncol 2009;27:2630-7
![Page 24: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/24.jpg)
J Clin Oncol 2009;27:2630-7
![Page 25: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/25.jpg)
J Clin Oncol 2009;27:2630-7
Significance threshold, one sided P 0.10≦
PCR2 (1.4%) vs 1 (0.8%)
![Page 26: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/26.jpg)
J Clin Oncol 2009;27:2630-7
![Page 27: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/27.jpg)
J Clin Oncol 2009;27:2630-7
![Page 28: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/28.jpg)
J Clin Oncol 2009;27:2630-7
Reduction in percentage positive Ki67 from baseline to day 15
Percentage of patient cases attaining a natural logarithm of percentage positive Ki67of less than 1 at day 15
![Page 29: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/29.jpg)
J Clin Oncol 2009;27:2630-7
![Page 30: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/30.jpg)
Part IIITreating endocrine resistance
![Page 31: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/31.jpg)
Fulvestrant vs. Exemestane post non-steroidal AI
J Clin Oncol 2008;26:1664-70.
3.7 monthsDuration 9.3 months
3.7 monthsDuration 8.3 months
P=0.6531
![Page 32: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/32.jpg)
Everolimus + tamoxifen vs. tamoxifen
• Randomized phase 2 study• 111 postmenopausal women• ER-positive advanced breast cancer• previously treated with an aromatase inhibitor• PFS – 8.6 months vs. 4.5 months, P = 0.002
• OS – median not reached vs. 24.4 months, P = 0.01
33rd Annual San Antonio Breast CancerSymposium, San Antonio, TX, December 8–12, 2010.
![Page 33: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/33.jpg)
![Page 34: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/34.jpg)
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Study design
• International• Double-blind randomized (2:1)• Phase 3 study• oral everolimus (10 mg qd) or matching
placebo in conjunction with exemestane (25 mg qd)
N Engl J Med 2011 Dec 7.
![Page 35: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/35.jpg)
• postmenopausal women• ER-positive• nonamplified HER2• refractory to previous letrozole or anastrozole – recurrence during or within 12 months after the
end of adjuvant treatment – progression during or within 1 month after the
end of treatment for advanced disease
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Patients
N Engl J Med 2011 Dec 7.
![Page 36: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/36.jpg)
• Primary: PFS • Secondary– overall survival– overall response rate– clinical benefit rate– time to deterioration of ECOG performance status– safety– Quality of life
• the European Organization for Research and Treatment of Cancer quality-of life core questionnaire (QLQ-C30)
• the breast cancer module (QLQ-BR23)
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
End point
N Engl J Med 2011 Dec 7.
![Page 37: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/37.jpg)
N Engl J Med 2011 Dec 7.
![Page 38: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/38.jpg)
N Engl J Med 2011 Dec 7.
![Page 39: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/39.jpg)
N Engl J Med 2011 Dec 7.
![Page 40: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/40.jpg)
N Engl J Med 2011 Dec 7.
![Page 41: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/41.jpg)
• Serious adverse events – combination-therapy vs. exemestane-alone – 23% (11% ) vs. 12% (1% )
• discontinue everolimus– adverse events
• 19% vs. 4%
– withdrawal of consent• 5% vs. 2%
• discontinue exemestane– adverse events
• 7% vs. 3%
– withdrawal of consent• 7% vs. 2%
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Safety
N Engl J Med 2011 Dec 7.
![Page 42: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/42.jpg)
6.9 vs. 2.8 msHR : 0.4395% CI : 0.35-0.54P<0.001
10.6 vs. 4.1 msHR : 0.3695% CI : 0.27-0.47P<0.001
N Engl J Med 2011 Dec 7.
![Page 43: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/43.jpg)
N Engl J Med 2011 Dec 7.
![Page 44: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/44.jpg)
N Engl J Med 2011 Dec 7.
![Page 45: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/45.jpg)
![Page 46: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/46.jpg)
![Page 47: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/47.jpg)
• immature at the time of the interim analysis– combination-therapy vs. exemestane-alone – 10.7% vs. 13%
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Overall survival
N Engl J Med 2011 Dec 7.
![Page 48: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/48.jpg)
Discussion
• Adverse events of everolimus– stomatitis, fatigue, asthenia, diarrhea, cough,
pyrexia, and hyperglycemia• Higher percentage of patients discontinued
everolimus because of a lack of tolerability
N Engl J Med 2011 Dec 7.
![Page 49: Endocrine resistance in breast cancer](https://reader035.fdocuments.net/reader035/viewer/2022062701/553a6e034a7959473a8b456c/html5/thumbnails/49.jpg)
Summary
• Addition of everolimus to endocrine therapy results in an improved clinical outcome
• Benefit should be weighed against the side effects observed with everolimus
• Potential of everolimus to benefit patient survival is not yet known